Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of antibody against o-acetylated gd2 ganglioside to improve the therapeutic potential of drugs

A ganglioside and antibody technology, which is applied in the direction of antibody medical components, anti-animal/human immunoglobulin, antibodies, etc., can solve problems such as toxicity and affecting pharmacokinetic processes

Pending Publication Date: 2019-10-08
OGD2 PHARMA +4
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these delivery systems affect the pharmacokinetic process of miRNA-based therapies and can also be toxic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of antibody against o-acetylated gd2 ganglioside to improve the therapeutic potential of drugs
  • Use of antibody against o-acetylated gd2 ganglioside to improve the therapeutic potential of drugs
  • Use of antibody against o-acetylated gd2 ganglioside to improve the therapeutic potential of drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0249] 1. Treatment of neuroblastoma and glioblastoma cells with anti-OAcGD2 mAb 8B6 induces pore formation in the cell membrane

[0250] Petri dishes (6 wells) were coated with 500 000 IMR5, LAN-1 or DUASOII cells / well for 24 hours and then treated with anti-OAcGD2 mAb 8B6 (mouse, IgG3) or isotype-matched negative control mouse IgG3 (CTRL-) Incubation. Then, 40 μg / ml of antibody was added to each well for 30 minutes. The supernatant was spun down and the cells were detached from their support using mechanical strength (without trypsin) and spun down. After washing with PBS, the cells were fixed with 2% glutaraldehyde in 0.1 mol / L sodium phosphate buffer (pH 7.4) for 1 hour at 4°C. with 1% OsO 4 Fixation was performed for 15 minutes. Dehydration was performed in ethanol baths using 25%, 50%, 75% and 100% ethanol for 15 min each. Finally, the cells were placed on metal stubs and analyzed by scanning electron microscopy.

[0251] Such as figure 1 As shown, pore formation ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.

Description

[0001] This patent application claims priority from European Patent Application 16002576.3 filed on December 5, 2016, which is hereby incorporated by reference. technical field [0002] The present invention relates to a composition comprising an anticancer agent and an antibody recognizing a specific O-acetylated form of GD2 ganglioside (i.e. OAcGD2 ganglioside), which enhances the uptake of said anticancer agent by cancer cells, And their use in methods of treating, preventing and / or managing certain cancers characterized by cells expressing OAcGD2 gangliosides. Background technique [0003] Delivery of anticancer agents to cells is a central aspect of therapeutic approaches against cancer. The biochemical properties of anticancer agents depend on their molecular weight, the pH of the environment, and their lipophilic and hydrophilic characteristics. [0004] Intersection of negatively charged cell membranes is the first step in delivering anticancer agents to cells. It ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395C07K16/30A61K39/00
CPCA61K39/39558C07K16/3084A61K2039/505C07K2317/24C07K2317/565C07K2317/73A61P35/00A61P35/02A61P35/04C07K2317/622
Inventor 斯蒂芬·比尔克莱朱利安·弗勒朗斯赛巴斯蒂安·法拉杰让-马可·勒·杜萨尔丹尼斯·科绍诺米奇卡尔·泰姆布里吉特·阿苏利纳
Owner OGD2 PHARMA